Background: The aim of this study was to investigate the clinical significance of serum β-2-microglobulin (B2M) in predicting the development of uremic pericarditis (UP) in patients with end-stage renal disease (ESRD).
Methods: Three hundred ESRD patients who started hemodialysis and underwent echocardiography were selected. The clinical data of 300 ESRD patients were obtained through the hospital medical record system. Serum B2M levels were measured 24 hours before starting hemodialysis. Risk factors for the occurrence of UP in ESRD patients were analyzed by logistic regression. Predictive value of serum B2M levels for the development of UP in ESRD patients was analyzed by ROC curve.
Results: Twenty-eight out of 300 ESRD patients developed UP. Serum B2M levels were higher in ESRD patients with UP. Higher serum B2M level was a risk factor for UP in ESRD patients. Serum B2M levels had a high predictive value for the development of UP in ESRD patients.
Conclusions: Serum B2M levels have a high predictive value for the development of UP in ESRD patients, and high serum B2M levels are associated with UP risk.